Education
About Us
Working with TipRanks
Follow Us
Prescient Therapeutics Limited (AU:PTX)
:PTX
RESEARCH TOOLSreports
PTX Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.06
Previous CloseN/A
Volume766.17K
Average Volume (3M)1.17M
Market Cap
AU$35.43M
Enterprise ValueAU$28.28M
Total Cash (Recent Filing)AU$8.41M
Total Debt (Recent Filing)AU$34.27K
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Sep 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding805,319,760
10 Day Avg. Volume1,561,079
30 Day Avg. Volume1,169,684
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)2.16
Price to Sales (P/S)0.00
P/FCF Ratio-3.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Prescient Therapeutics Limited News
PremiumCompany Announcements
Prescient Therapeutics Expands PTX-100 Clinical Trials to U.S.PremiumCompany Announcements
Prescient Therapeutics Extends Securities Issue Deadline
PremiumCompany Announcements
Prescient Therapeutics Announces Cessation of Securities
PremiumCompany Announcements
Prescient Therapeutics Announces Cessation of Securities
PremiumCompany Announcements
Prescient Therapeutics Launches $7 Million Share Purchase PlanOptions Prices
Currently, No data available
---
Ownership Overview
2.22% Insiders
―
Mutual Funds
― Other Institutional Investors
97.78% Public Companies and
Individual Investors
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.06 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$35.43M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Sep 01, 2025 which is in 44 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 805,319,760 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
Prescient Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PTX Sentiment 70%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth AU$21.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.30%
12-Months-Change
Fundamentals
Return on Equity
-36.95%
Trailing 12-Months
Asset Growth
-33.04%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.